What is the 13F Pro Quality Score for ENTX?

13F Pro ranks Entera Bio Ltd. (ENTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENTX's current score at https://13fpro.ai/research/ENTX (free sign-up required for the full ranking).

Where does 13F Pro source ENTX data?

All Entera Bio Ltd. fundamentals and ownership data come directly from SEC EDGAR. Entera Bio Ltd. files with the SEC under CIK 1638097. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENTX in?

Entera Bio Ltd. (ENTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENTX research updated on 13F Pro?

ENTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Entera Bio Ltd.(ENTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1638097 ENTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ENTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Entera Bio Ltd. (ENTX), a Healthcare sector company. ENTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Entera Bio Ltd. reports net income of $-3.5M, free cash flow of $-3.1M. Top institutional holders of ENTX by reported 13-F value include Knoll Capital Management,, RENAISSANCE TECHNOLOGIES, Parkman Healthcare Partners, based on the most recent SEC filings. ENTX trades on the Nasdaq exchange and files with the SEC under CIK 1638097. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Entera Bio Ltd. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-3.5M

Free Cash Flow

Q1 2026

$-3.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$42.0KFY 2025

FY21 $571.0KFY22 $134.0KFY23 $0.00FY25 $42.0K

Net Income

-28.7% YoY

$-11.4MFY 2025

FY21 $-12.2MFY22 $-13.1MFY23 $-8.9MFY25 $-11.4M

Operating Income

-29.7% YoY

$-11.5MFY 2025

FY21 $-12.2MFY22 $-13.0MFY23 $-8.9MFY25 $-11.5M

EPS (Diluted)

-19.4% YoY

$0.25FY 2025

FY21 $0.47FY22 $0.45FY23 $0.31FY25 $0.25

Total Assets

+35.9% YoY

$16.0MFY 2025

FY21 $26.0MFY22 $13.1MFY23 $11.8MFY25 $16.0M

Op. Cash Flow

-0.8% YoY

$-7.4MFY 2025

FY21 $-9.1MFY22 $-12.5MFY23 $-7.3MFY25 $-7.4M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$42.0K	$0.00 -100.0%	$134.0K -76.5%	$571.0K +56.4%	$365.0K
Net Income	$-11.4M -28.7%	$-8.9M +32.0%	$-13.1M -7.3%	$-12.2M -8.7%	$-11.2M
Operating Income	$-11.5M -29.7%	$-8.9M +31.7%	$-13.0M -6.5%	$-12.2M -9.4%	$-11.2M
EPS (Diluted)	$0.25 -19.4%	$0.31 -31.1%	$0.45 -4.3%	$0.47	—
Total Assets	$16.0M +35.9%	$11.8M -10.4%	$13.1M -49.5%	$26.0M +153.2%	$10.3M
Operating Cash Flow	$-7.4M -0.8%	$-7.3M +41.5%	$-12.5M -37.9%	$-9.1M +14.2%	$-10.6M

AI Insight: ENTX Financial Trends

Entera Bio shows zero revenue generation while burning through equity base, with losses accelerating to $4M in Q1 2026.

• Revenue remains at $0M across all quarters with no signs of commercialization progress.

• Net losses worsened from $2M in Q4 2025 to $4M in Q1 2026.

• Equity declined from $19M in Q1 2025 to $11M in Q1 2026, indicating ongoing cash burn.

⚠ Operating cash flow deteriorated to negative $3M in Q1 2026 from negative $1M in prior quarters.

⚠ Current equity runway suggests limited operating capacity without additional funding given accelerating burn rate.

AI Insight: ENTX Ratio Trends

ROE deteriorated sharply to -131.2% in Q1 2026 from -53.0% in Q1 2025, indicating worsening profitability trends.

• ROE declined from -53.0% in Q1 2025 to -131.2% in Q1 2026, showing accelerating losses.

• ROA worsened from -47.5% in Q1 2025 to -75.4% in Q4 2025 before data gaps emerged.

• ROIC deteriorated from -52.9% in Q1 2025 to -92.9% in Q4 2025, reflecting declining operating efficiency.

⚠ Missing operating margin and net profit margin data across all periods limits visibility into core profitability drivers.

⚠ Consistent negative returns across all metrics suggest ongoing operational challenges requiring monitoring for improvement signs.

Get alerted when ENTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Entera Bio Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENTX

Knoll Capital Management, LLC
$6.5M5,881,879 sh
RENAISSANCE TECHNOLOGIES LLC
$525.5K473,442 sh
Parkman Healthcare Partners LLC
$320.4K288,670 sh
CITADEL ADVISORS LLC
$272.6K245,577 sh
Seven Fleet Capital Management LP
$228.2K205,542 sh
MARSHALL WACE, LLP
$217.3K195,780 sh
NORTHERN TRUST CORP
$163.0K146,854 sh
XTX Topco Ltd
$146.1K131,622 sh
Schonfeld Strategic Advisors LLC
$61.3K55,223 sh
SIGNATURE ESTATE & INVESTMENT ADVISORS LLC
$52.5K47,328 sh

Fund	Value	Shares
Knoll Capital Management, LLC	$6.5M	5,881,879
RENAISSANCE TECHNOLOGIES LLC	$525.5K	473,442
Parkman Healthcare Partners LLC	$320.4K	288,670
CITADEL ADVISORS LLC	$272.6K	245,577
Seven Fleet Capital Management LP	$228.2K	205,542
MARSHALL WACE, LLP	$217.3K	195,780
NORTHERN TRUST CORP	$163.0K	146,854
XTX Topco Ltd	$146.1K	131,622
Schonfeld Strategic Advisors LLC	$61.3K	55,223
SIGNATURE ESTATE & INVESTMENT ADVISORS LLC	$52.5K	47,328

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENTX on your watchlist

Track score changes the day Entera Bio Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENTX a good stock to buy?

13F Pro's AI-powered analysis of Entera Bio Ltd. (ENTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENTX are available on the ENTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ENTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Entera Bio Ltd.'s investment landscape.